Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Portola Pharmaceuticals Inc patents


Recent patent applications related to Portola Pharmaceuticals Inc. Portola Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Portola Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Portola Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Portola Pharmaceuticals Inc-related inventors


Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity

This invention is related to the field of pcsk9 biology and the composition and methods of use of small organic compounds as ligands for modulation of pcsk9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein pcsk9. ... Portola Pharmaceuticals Inc

Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity

This invention is related to the field of pcsk9 biology and the composition and methods of use of small organic compounds as ligands for modulation of pcsk9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein pcsk9. ... Portola Pharmaceuticals Inc

Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor xa inhibitor.. ... Portola Pharmaceuticals Inc

Inhibitors of protein kinases

The present invention is directed to compounds of formula i-ii and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or jak kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or jak kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or jak kinase activity, such as undesired thrombosis and non hodgkin's lymphoma.. ... Portola Pharmaceuticals Inc

Modulation of factor xa inhibitor-mediated blood loss by partial and transient administration of antidote

The present disclosure provides unit dose formulations and methods to reduce, stop or prevent bleeding in a patient undergoing anticoagulant therapy with a factor xa inhibitor. The methods entail at least partial neutralization of the factor xa inhibitors the unit dose formulations and methods of the present disclosure can be effective even after actual bleeding has initiated.. ... Portola Pharmaceuticals Inc

Cerdulatinib for the treatment of b-cell malignancies

Provided herein are compositions and methods for treating a relapsed or refractory hematologic cancer in a human patient in need thereof. The methods entail administering to the patient a daily dose of about 10 mg to about 75 mg of cerdulatinib or a pharmaceutically acceptable salt thereof, wherein the patients suffer one or more of a b-cell malignancy, chronic lymphocytic leukemia (cll), follicular lymphoma (fl), diffuse large b-cell lymphoma (dlbcl) or other transformed fl and/or have relapsed or not responded to a prior chemotherapy.. ... Portola Pharmaceuticals Inc

Prevention and treatment of thrombosis in medically ill patients

Provided herein are methods for preventing and treating thrombosis in medically ill patients by administering to the patient a therapeutically effective amount of betrixaban.. . ... Portola Pharmaceuticals Inc

Preparation of factor xa derivatives

The present disclosure provides methods for manufacturing a fxa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (sti)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.. ... Portola Pharmaceuticals Inc

Process for making recombinant antidote to factor xa inhibitor

Disclosed are methods and isolated cells useful for the improved production of function fxa derivative protein that acts as a fxa inhibitor antidote. One aspect relates to an isolated cell comprising the r-antidote polynucleotide and furin polynucleotide. ... Portola Pharmaceuticals Inc

Antidotes for factor xa inhibitors and methods of using the same

The present invention relates antidotes to anticoagulants targeting factor xa. The antidotes are factor x and factor xa protein derivatives that bind to the factor xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. ... Portola Pharmaceuticals Inc

Pyridazine compounds as jak inhibitors

In one aspect, the invention provides a compound according to formula i, as well as tautomers, pharmaceutically acceptable salts, and hydrates thereof. Pharmaceutical compositions, methods of inhibiting janus kinases (jaks), and methods for treating a condition or disorder mediated at least in part by jak kinase activity are also described.. ... Portola Pharmaceuticals Inc

Cerdulatinib for treating myeloma

Compositions and methods for treating multiple myeloma (mm), acute myeloid lymphoma (aml) or a myeloproliferative disease (mpd) in a human patient in need thereof. The methods entail administering to the patient an effective amount of cerdulatinib.. ... Portola Pharmaceuticals Inc

Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor xa inhibitor.. ... Portola Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Portola Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Portola Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###